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ABSTRACT
Background. Whether neutrophil-to-lymphocyte ratio
(NLR) predicts survival of patients with colorectal liver
metastases (CLM) treated with systemic chemotherapy
remains unclear.
Methods. Clinicopathologic data were reviewed for
patients with CLM treated with chemotherapy and resec-
tion (n = 200) or chemotherapy only (n = 90). Univariate
and multivariate analyses for prognostic factors were per-
formed. In the resection group, whether chemotherapy
normalizes high NLR and the effect of NLR normalization
on survival were evaluated.
Results. In the resection group, patients with preoperative
NLR [ 5 had a worse 5-year survival rate than patients
with NLR B 5 (19% vs. 43%; P = 0.009), and NLR [ 5
was the only independent preoperative predictor of worse
survival (P = 0.016; hazard ratio [HR] = 2.22; 95% con-
fidence interval [95% CI], 1.16–4.25). In the nonresection
group, patients with prechemotherapy NLR [ 5 had a
worse 3-year survival rate than patients with NLR B 5 (0%
vs. 23%; P = 0.0002), and NLR [ 5 was the only inde-
pendent predictor of worse survival (P = 0.001;
HR = 2.91; 95% CI, 1.54–5.50). In the resection group,
chemotherapy normalized high NLR in 17 of 25 patients,
and these 17 patients had better survival than the 8 patients
with high NLR both before chemotherapy and before sur-
gery (P = 0.021).
Conclusion. NLR independently predicts survival in
patients with CLM treated with chemotherapy followed by
resection or chemotherapy only. When chemotherapy
normalizes high NLR, improved survival is expected.
Several prognostic factors have been identified for
patients with colorectal liver metastases (CLM) undergoing
hepatic resection.1–4 These include patient age, primary
tumor stage, disease-free interval (DFI), carcinoembryonic
antigen (CEA) level, tumor size, tumor number, whether
the CLM are bilateral, and surgical margin status. How-
ever, clinical risk scores based on these prognostic factors
were not validated in recent studies of patients undergoing
hepatic resection.1–3,5–8
Unfortunately, few patients with CLM are eligible for
hepatic resection, and prognostic factors for patients treated
solely with chemotherapy are not well defined.9 Further,
with the increasing use of preoperative chemotherapy in
both resectable and unresectable CLM, the population of
patients who can benefit from hepatic resection has also
changed. Adam et al. showed that 12.5% of patients with
initially unresectable CLM had their disease converted to
resectable by chemotherapy and that the 5-year survival
rate after hepatic resection in these patients was 33%.10
These results suggest that we cannot predict the outcome of
patients with CLM before chemotherapy. The prognostic
factors proposed to date may have limited usefulness in
patients who receive preoperative chemotherapy.
Recently, high serum C-reactive protein level (CRP), high
neutrophil-to-lymphocyte ratio (NLR), and weak histologic
lymphocyte infiltration around the tumor have been reported
to be associated with poor prognosis in patients with
CLM.7,11–13 A recent study by Malik et al. showed that only
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the host inflammatory response, defined as NLR [ 5 or
CRP [ 10 mg/l, and tumor number independently predicted
disease-free and overall survival after resection of CLM.7
The inflammatory response suggested by CRP or NLR is
useful because it can be easily measured by preoperative
blood sampling. Although preoperative NLR has been
shown to be associated with outcomes after the resection of
primary tumor or liver metastases, its usefulness has not been
well demonstrated in patients with CLM treated with che-
motherapy. Malik et al. found that preoperative
chemotherapy for CLM did not normalize high NLR; how-
ever, the number of patients in that study who received
preoperative chemotherapy was small, and the authors did
not show detailed results regarding the degree to which high
NLR was normalized by chemotherapy.7,13 Therefore, it
remains to be confirmed whether prechemotherapy NLR is a
useful prognostic factor in patients with CLM.
The goal of this study was to evaluate whether NLR
before chemotherapy or hepatic resection predicts the
survival of patients with isolated CLM treated with sys-
temic chemotherapy followed by resection or systemic
chemotherapy alone. In addition, we evaluated whether
chemotherapy normalizes high NLR and the effect of NLR
normalization on survival.
METHODS
This study was approved by our institutional review
board (IRB DR08–0143), which waived the requirement
for informed consent. We selected two groups of patients
with liver-only metastases from colorectal cancer—those
who underwent preoperative chemotherapy followed by
hepatic resection and those who underwent chemotherapy
only.
For the resection group, we identified 340 patients at our
institution who underwent curative resection of CLM after
preoperative chemotherapy between September 1997 and
June 2007 from our prospectively collected database on
hepatic resection. Chemotherapy regimens consisted of a
fluoropyrimidine plus irinotecan or oxaliplatin, and no
patient received other chemotherapy within 6 months
before the preoperative chemotherapy. Because we wished
to focus on the effect of NLR in patients with liver-only
metastases, 35 patients were excluded because hepatic
resection preceded resection of primary tumors (n = 23) or
because patients had synchronous resection of primary
tumors at the time of hepatectomy (n = 12). Three patients
who were lost to follow-up were also excluded. Of the
remaining 302 patients, the 200 patients who had NLR
measurements available both before preoperative chemo-
therapy and between preoperative chemotherapy and
hepatic resection were included.
For the nonresection group, we identified 93 patients
who were treated with chemotherapy after resection of
primary tumors but who did not undergo hepatic resection
for unresectable liver-only CLM between September 1997
and June 2007. As in the resection group, chemotherapy
regimens consisted of a fluoropyrimidine plus irinotecan or
oxaliplatin. Of these 93 patients, three patients who were
lost to follow-up were excluded. The remaining 90 patients
who were treated with chemotherapy for liver-only CLM
were included in the study.
In all 290 patients, the following factors were reviewed:
status of lymph node metastasis of primary lesion, DFI,
CEA level, tumor (CLM) number and size (diameter of the
largest nodule), and NLR. DFI was defined as the period
from the date of resection of the primary tumor to the date
of diagnosis of CLM. NLR was calculated as neutrophil
count divided by lymphocyte count, and no patient had
clinical signs of sepsis at the time of blood sampling for
NLR. NLR [ 5 was defined as high, in accordance with the
practice in previous studies.7,13,14
For patients in the resection group, tumor number and
size, CEA level, and NLR were evaluated both before
chemotherapy and before surgery. Tumor number and size
were determined before chemotherapy and before surgery
on the basis of radiologic findings and after surgery on the
basis of pathologic findings. Type of hepatic resection and
surgical margin status were also reviewed. Hemihepatec-
tomy and extended hemihepatectomy were considered to
be major hepatectomy; all other procedures were consid-
ered to be minor hepatectomy. Positive surgical margin
was defined as the presence of exposed tumor along the
line of transection, presence of tumor cells at the line of
transection detected by histologic examination, or micro-
scopic margins of \1 mm.15
Univariate and multivariate analyses were performed to
identify prognostic predictors available before chemother-
apy or hepatic resection. In addition, the number of patients
in the resection group who experienced normalization of
NLR as a result of chemotherapy and how such normali-
zation affected outcome were analyzed.
Continuous data were expressed as median and range and
compared by the Mann-Whitney U-test. The primary end-
point was overall survival. For analyses of the entire patient
cohort and the nonresection group, survival was calculated
from the date of initiation of chemotherapy. For analysis of
patients in the resection group, survival was calculated from
the date of surgery. Survival curves were made by the
Kaplan-Meier method and compared by the log-rank test.
Univariate and multivariate analyses to identify prognostic
predictors were performed by Cox proportional hazard
regression models. Variables with P \ 0.10 on univariate
analysis were entered into multivariate analyses. P \ 0.05
was considered statistically significant in all analyses.
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RESULTS
Profiles
In the hepatic resection group (n = 200), the median
patient age was 57 years (range, 23–86 years), and 132
patients (66%) were male. Preoperative chemotherapy
regimens consisted of a fluoropyrimidine and one of the
following: irinotecan (n = 75), irinotecan with bev-
acizumab (n = 20), oxaliplatin (n = 35), oxaliplatin with
bevacizumab (n = 59), and irinotecan and oxaliplatin
(n = 11). The median number of chemotherapy cycles was
four (range, 2–23), and the median interval between the last
dose of chemotherapy and hepatic resection was 42 days
(range, 14–174 days).
In the nonresection group (n = 90), the median patient
age was 56 years (range, 26–81 years), and 61 patients
(68%) were male. Chemotherapy regimens consisted of a
fluoropyrimidine and one of the following: irinotecan
(n = 40), irinotecan with bevacizumab (n = 8); oxaliplatin
(n = 10), oxaliplatin with bevacizumab (n = 17), and iri-
notecan and oxaliplatin (n = 15). The median number of
first-line chemotherapy cycles was six (range, 1–26).
Changes in Clinicopathologic Features After
Chemotherapy in the Resection Group
In the resection group, CEA level, tumor number, and
tumor size were statistically significantly decreased after
chemotherapy. Specifically, median (range) values before
chemotherapy and before surgery were as follows: CEA
level: 8.5 (1.0–4513.4) ng/ml, 2.8 (1.0–670.7) ng/ml,
P \ 0.001; tumor number: 2.5 (1–32), 2.0 (0–15),
P \ 0.001; and tumor size: 3.4 (.5–19.0) cm, 2.4 (.0–16.5)
cm, P \ 0.001.
In addition, tumor number was larger at pathologic
examination than by preoperative radiologic assessment
(median [range], mean: 2.0 [1–24], 3.5 vs. 2.0 [0–15], 2.8;
P \ 0.001). Likewise, tumor size was larger on pathologic
examination than on preoperative radiologic assessment
(median [range], mean; 2.5 [.5–17.0], 3.5 cm vs. 2.4 [.0–
16.5], 3.0 cm; P \ 0.001).
Prognostic Factors for All Patients
For the entire study group of 290 patients, the median
follow-up time from the date of initiation of chemotherapy
was 29 months (range, 3–105 months). Cumulative 1-, 3-,
and 5-year survival rates were 91%, 63%, and 34%,
respectively.
Thirty-nine patients (13%) had NLR [ 5 before che-
motherapy. Cumulative 1-, 3-, and 5-year survival rates
were 77%, 47%, and 26%, respectively, in the patients with
NLR [ 5 before chemotherapy and 92%, 65%, and 36%,
respectively, in the patients with NLR B 5 before chemo-
therapy (P = 0.017) (Fig. 1).
The results of univariate and multivariate analysis for
the predictors of survival in all 290 patients are listed in
Table 1. On univariate analysis, predictors of worse sur-
vival were male sex, DFI \1 year, CEA level [200 ng/ml,
multiple tumors, tumor size [5 cm, no resection, and
NLR [ 5. Of these factors, male sex, no resection, and
NLR [ 5 remained independent predictors of worse sur-
vival on multivariate analysis.
Prognostic Factors for the Resection Group
For the 200 patients who underwent hepatic resection,
the median follow-up period after hepatic resection was
28 months (range, 2–102 months). Cumulative 1-, 3-, and
5-year survival rates were 96%, 68%, and 41%,
respectively.
Twenty patients (10%) had NLR [ 5 before surgery.
Cumulative 1-, 3-, and 5-year survival rates were 100%,
38%, and 19%, respectively, in the patients with NLR [ 5
before surgery and 96%, 70%, and 43%, respectively, in
the patients with NLR B 5 before surgery (P = 0.009)
(Fig. 2). NLR before chemotherapy did not predict survival
(5-year survival rate, NLR [ 5 vs. B 5, 42% vs. 41%,
P = 0.324).
The results of univariate and multivariate analysis for
the predictors of survival are provided in Table 2. On
univariate analysis, predictors of worse survival were
concomitant radiofrequency ablation (RFA), multiple
tumors in the pathologic specimen, and preoperative
NLR [ 5. Male sex and positive surgical margins were
marginally statistically significant predictors of worse
survival. On multivariate analysis that used variables
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FIG. 1 Survival of all patients according to NLR before
chemotherapy
616 Y. Kishi et al.
available before surgery (sex, NLR), only NLR [ 5 was an
independent predictor of worse survival (Table 2). On
multivariate analysis that used variables available after
surgery (sex, RFA, multiple tumors, surgical margin status,
NLR), concomitant RFA, positive surgical margin, and
NLR [ 5 were independent predictors of worse survival
(Table 2).
Prognostic Factors for the Nonresection Group
For the 90 patients who did not undergo hepatic resec-
tion, the median follow-up period after the initiation of
chemotherapy was 16 months (range, 3–99 months). Two
patients (2%) had no radiologic evidence of disease after
follow-up of 99 and 55 months, respectively. Cumulative
1-, 3-, and 5-year survival rates were 74%, 20%, and 12%,
respectively.
Fourteen patients (16%) had NLR [ 5 before chemo-
therapy. Cumulative 1-, 3-, and 5-year survival rates were
40%, 8%, and 0%, respectively, in the patients with
NLR [ 5 before chemotherapy and 78%, 40%, and 23%,
respectively, in the patients with NLR B 5 before chemo-
therapy (P = 0.0002) (Fig. 3).
The results of univariate and multivariate analysis for
the predictors of survival are listed in Table 3. Univariate
analysis revealed that NLR [ 5 was a predictor of worse
survival. Male sex was a marginally statistically significant
predictor of worse survival. NLR [ 5 remained an inde-
pendent predictor of worse survival on multivariate
analysis.
TABLE 1 Univariate and multivariate analysis of prognostic predictors in 290 patients
Variable N 1-y
survival
(%)
3-y
survival
(%)
5-y
survival
(%)
Median
survival
(mo)
Univariate analysis Multivariate analysis
P value HR 95% CI P value HR 95% CI
Sex
Male 193 90 60 28 41 0.015 1.6 1.1–2.3 0.029 1.6 1.1–2.3
Female 97 93 68 50 56
Age (year)
[60 103 90 66 34 48 0.581 0.9 0.6–1.3
B60 187 91 61 34 42
Lymph node metastasis of primary tumor
Positive 215 90 58 37 42 0.461 1.2 0.8–1.8
Negative 37 93 76 26 48
DFI (y)
\1 230 88 57 30 39 \0.001 2.6 1.5–4.5 .139 1.6 0.9–3.0
C1 60 100 86 54 65
CEA (ng/ml)a
[200 43 86 38% 22 26 0.003 1.9 1.2–2.8 0.969 1.0 0.6–1.6
B200 240 91 67 37 47
Tumor
numbera
Multiple 272 90 58 29 40 \0.001 2.9 1.6–5.1 .057 1.8 1.0–3.2
Solitary 87 95 81 63 NA
Tumor size
(cm)a
[5 81 88 58 27 38 0.010 1.4 0.9–2.0 0.111 1.4 0.9–2.0
B5 199 92 64 39 47
Treatment
No Hx 90 74 20 12 18 \0.001 5.3 3.8–7.5 \0.001 4.7 3.2–7.1
Hx 200 98 81 44 54
NLRa
[5 39 77 47 26 34 0.019 1.7 1.1–2.7 0.005 2.0 1.3–3.3
B5 251 92 65 36 45
HR hazard ratio, 95% CI 95% confidence interval, NA not available, DFI disease-free interval, CEA carcinoembryonic antigen, Hx hepatic
resection, NLR neutrophil-to-lymphocyte ratio
a Measured before chemotherapy
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Influence of Preoperative Chemotherapy on NLR
in Patients in the Resection Group
In the resection group, 25 patients (12.5%) had
NLR [ 5 before chemotherapy, and 17 of these patients
(68%) had NLR B 5 before surgery. In contrast, 175
patients had NLR B 5 before chemotherapy, and 12 of
these patients (6.9%) had NLR [ 5 before surgery.
Cumulative 1-, 3-, and 5-year survival rates of the 17
patients with improved NLR were 94%, 63%, and 50%,
respectively, similar to the corresponding rates in the 163
patients with NLR B 5 both before chemotherapy and
before surgery (96%, 73%, and 43%, respectively,
P = .991) and better than those in the 8 patients with
NLR [ 5 both before chemotherapy and before surgery
(P = .021) (Fig. 4).
DISCUSSION
The present study showed that high NLR (NLR [ 5)
independently predicted worse survival in patients with
CLM treated with chemotherapy followed by hepatic
resection or chemotherapy only. Although the patients
included in the resection and nonresection groups were
different, especially with respect to tumor burden, we
evaluated the prognostic predictors in the whole group as
well as in each subgroup because resectability of CLM
cannot always be predicted before preoperative chemo-
therapy. In multivariate analysis of all patients, NLR [ 5
was shown to be an independent predictor of worse sur-
vival, along with male sex and absence of hepatic
resection, and neither tumor size nor tumor number pre-
dicted survival. This result suggests either that high NLR
indicates aggressive tumor biology associated with poor
outcomes that cannot be estimated on the basis of
previously proposed risk factors, including tumor size and
tumor number, or that high NLR may indicate impaired
host immune response to the tumor. A pathologic study by
Canna et al. showed that increased infiltration of CD4? T
lymphocytes within colorectal cancer was associated with
lower CRP and better prognosis.16
Furthermore, multivariate analysis in the resection and
nonresection subgroups showed that high NLR was the
only factor among the factors that are available before
treatment that predicted survival. It was notable that none
of the five factors included in the clinical risk score (lymph
node metastasis, DFI \ 1 year, CEA [ 200 ng/ml, tumor
size [ 5 cm, multiple tumors) predicted survival.2
Although the reliability of a clinical risk score proposed on
the basis of a single-institution study may be affected by
patient selection bias, failure of clinical risk scores to
predict prognosis was also reported in several recent
studies at other high-volume centers.6,7 Therefore, it seems
reasonable to conclude that scores based only on the classic
clinicopathologic factors have limited ability to predict
survival in patients with CLM. Another problem with
clinical risk scores is that in most studies, there is no clear
discrimination between tumor number and tumor size
estimated preoperatively on the basis of radiologic findings
and tumor number and tumor size defined postoperatively
on the basis of pathologic evaluation. In other words, tumor
number and tumor size may be underestimated on preop-
erative evaluation. Recent studies showed that the
sensitivity of contrast-enhanced computed tomography in
the detection of CLM was only 60% to 73%.17–19 The
present study also revealed that in the resection group,
tumor number was lower and tumor size was smaller on
preoperative assessment than on pathologic examination.
Our results showed that NLR is a better prognostic pre-
dictor than tumor number and tumor size, regardless of
whether they are assessed radiologically or pathologically.
In the analysis for the resection group that used the
variables available postoperatively, concomitant RFA and
positive surgical margins were the only independent pre-
dictors besides high NLR. We previously reported that the
combination of RFA with resection was associated with a
higher risk of intrahepatic tumor recurrence and worse
survival.20 Positive surgical margin is also an indicator of
incomplete resection. Therefore, the current analysis of
patients who underwent hepatic resection suggests the
importance of complete resection of CLM, although
incomplete resection may occur, especially in patients with
multiple or bilobar metastases.15,21 To achieve complete
resection, two-stage hepatectomy in combination with
portal vein embolization is a better option than concomitant
RFA.22–24
In contrast to Malik et al., who found that neoadjuvant
chemotherapy did not normalize a high NLR, we found
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FIG. 2 Survival of patients who underwent hepatic resection
according to NLR after chemotherapy but before resection
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TABLE 2 Univariate and multivariate analysis of prognostic predictors in the 200 patients who underwent hepatic resection
Variable N 3 yr
survival
(%)
5 yr
survival
(%)
Median
survival
(m)
Univariate analysis Multivariate analysis
(preoperative factors)
Multivariate analysis
(postoperative factors)
P value HR 95% CI P value HR 95% CI P value HR 95% CI
Sex 0.055 1.7 1.0–3.0 0.07 1.7 1.0–2.9 0.131 1.5 0.9–2.7
Male 132 64 35 42
Female 68 76 53 NA
Age (y) 0.739 1.1 0.7–1.8
[60 80 66 34 45
B60 120 68 43 45
DFI (y) 0.202 1.5 0.8–2.6
B1 140 64 39 44
[1 60 78 45 59
Lymph node
metastasis
of primary tumor
0.702 0.9 0.5–1.6
Positive 140 69 46 57
Negative 53 71 30 44
Hepatectomy 0.191 1.5 0.83– 2.54
Major 138 66 37 44
Minor 62 73 50 53
Concomitant RFA 0.003 2.0 1.3–3.3 0.021 1.9 1.1–3.2
Yes 64 59 26 37
No 136 72 51 62
CEA (ng/mL)a 0.144 2.4 0.7–7.6
[200 4 75 0 37
B200 196 68 42 48
Tumor number
Preoperativea 0.117 1.6 0.9–2.9
Multiple 140 64 36 44
Solitary 60 78 57 NA
Pathology 0.040 2.0 1.0–3.8 0.427 1.3 0.7–2.7
Multiple 147 63 34 44
Solitary 53 83 61 NA
Tumor size (cm)
Preoperativea 0.497 1.3 .7–2.4
[5 27 66 37 44
B5 167 70 42 49
Pathology 0.807 1.1 .6–1.9
[5 35 71 44 45
B5 165 67 45 48
Surgical margin 0.068 1.9 1.0–3.9 0.031 2.3 1.1–4.7
Positive 20 37 15 33
Negative 180 71 43 48
NLRa 0.011 2.3 1.2–4.4 .016 2.2 1.2–4.3 0.048 2.0 1.0–3.8
[5 20 40 19 34
B5 180 71 43 49
HR hazard ratio, 95% CI 95% confidence interval, NA not available, DFI disease-free interval, CEA carcinoembryonic antigen, Hx hepatic
resection, NLR neutrophil-to-lymphocyte ratio
a Measured before hepatic resection
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that high NLR reverted to normal after preoperative che-
motherapy in 17 patients (68%).7,13 The survival of these
17 patients was similar to that of patients with NLR B 5
both before chemotherapy and before surgery. The survival
of the 17 patients with normalized NLR also was better
than that of the patients whose NLR remained high.
Perhaps because of the high rate of conversion from
high NLR to low NLR in our data set, high NLR before
chemotherapy was not associated with worse survival in
the resection group. We did not assess the rate of conver-
sion from NLR [ 5 to NLR B 5 after chemotherapy in the
nonresection group because most patients in that group
were shifted to second-line chemotherapy after evidence of
disease progression without a chemotherapy-free interval
required to accurately ascertain the NLR. Further pro-
spective studies are needed to evaluate the relative
contributions of NLR normalization to the improved sur-
vival in patients who undergo hepatic resection.
Although we demonstrated the usefulness of NLR as a
prognostic factor, it would not be appropriate to conclude
that hepatic resection should be withheld only because
preoperative NLR is high. In addition, there is a possibility
that inflammatory response was underestimated in the
present study. First, the proportion of patients with high
NLR before hepatic resection in the resection group was
10% (20 of 200), lower than the 18% (78 of 440) reported
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FIG. 3 Survival of patients who did not undergo hepatic resection
according to NLR before chemotherapy
TABLE 3 Univariate and multivariate analysis of prognostic factors in the 90 patients who underwent chemotherapy without hepatic resection
Variable N 1 yr
survival
(%)
3 yr
survival
(%)
5 yr
survival
(%)
Median
survival
(m)
Univariate analysis Multivariate analysis
P value HR 95% CI P value HR 95% CI
Sex
Male 61 72 15 8 16 0.080 1.6 0.9–2.7 0.152 1.5 0.9–2.5
Female 29 75 29 22 22
Age (y)
[60 23 70 15 15 20 0.721 1.1 0.7–1.9
B60 67 74 22 11 18
Lymph node metastasis
of primary tumor
Positive 75 73 18 11 18 0.860 1.7 0.6–2.0
Negative 14 71 26 17 18
CEA (ng/mL)a
[200 27 77 16 11 16 0.902 1.0 0.6–1.7
B200 63 69 21 12 18
Tumor numbera
Multiple 85 74 18 10 18 0.216 2.5 0.6–1.5
Solitary 5 53 53 53 NA
Tumor size (cm)a
[5 30 66 13 13 15 0.165 1.4 0.9–2.4
B5 59 76 24 12 19
NLRa
[5 14 40 0 0 11 \0.001 3.1 1.7–5.9 0.001 2.9 1.5–5.5
B5 76 78 23 14 21
HR hazard ratio, 95% CI 95% confidence interval, NA not available, CEA carcinoembryonic antigen, NLR neutrophil-to-lymphocyte ratio
a Measured before chemotherapy
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in the study of Halazun et al. (P = 0.0156).13 In addition,
the cutoffs of high NLR or CRP defined as [5 or [10 mg/l
were empirical and were not validated by quantitative
analyses. In the study of Malik et al., high CRP ([10 mg/l)
was used in addition to NLR as an index of the presence of
inflammatory response to tumor, and 24.5% of patients
(137 of 423) met these criteria.7 Patients in the resection
group in our series underwent hepatic resection a median of
6 weeks after the last chemotherapy, and in 92% of cases
(183 of 200), the interval was 4 weeks or more. Hence, the
influence of immunosuppression by chemotherapy was
minimized, but it cannot be completely ruled out. Leitch
et al. reported that Glasgow prognostic score, which is
based on high CRP ([10 mg/l, score 1) and hypoalbumi-
nemia (\35 g/l, score 1), was better than NLR as a
predictor of prognosis in patients with colorectal can-
cer.25,26 Because CRP is not routinely measured in our
institution, we could not analyze CRP or Glasgow prog-
nostic score in the present study. Second, although high
NLR is considered to reflect weak lymphocyte-mediated
immune response to tumor as a result of relative lympho-
cytopenia, previous studies evaluating histologic
infiltration of inflammatory cells around or within colo-
rectal cancer showed that not only lymphocyte infiltration
but also infiltration of macrophages, eosinophils, mast
cells, and natural killer cells is associated with better
prognosis.13,16,27–29 Furthermore, there is a possibility that
exclusion of one-third (102 of 300) of patients as a result of
the absence of NLR data may potentially bias the results of
the present study.
In conclusion, high NLR (NLR [ 5) is a useful pre-
dictor of worse survival in patients with CLM treated with
either chemotherapy alone or with chemotherapy followed
by hepatic resection. When chemotherapy normalizes high
NLR and hepatic resection is performed, survival can be
expected to be similar to that of patients who have normal
NLR both before chemotherapy and before surgery. Fur-
ther prospective studies evaluating the inflammatory
response indices, including NLR, CRP, and cytokines, in a
larger numbers of patients are needed to comprehensively
identify the patients with inflammatory response at high
risk for poor outcomes.
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